Exalenz Bioscience's Board of Directors has approved pursuing the development of liver diagnostics in four medical indications: Clinically Significant Portal Hypertension (CSPH), Nonalcoholic Steatohepatitis (NASH), Hepatocellular Carcinoma (HCC), and Acute Liver Failure (ALF). Exalenz, which develops and markets unique diagnostic and monitoring systems for the diagnosis and management of digestive tract and liver diseases, reports that the company's Board of Directors has approved a strategic and tactical plan, expanding and accelerating the company's activity in the field of liver diagnostics. Exalenz is expected to commence its pivotal Phase III trial in the third quarter of 2014, for the diagnosis of clinically significant portal hypertension (CSPH).

Working with the FDA, Exalenz has developed an approach to the diagnosis of CSPH comparing breath testing to HVPG (Hepatic Vein Venus Pressure) that will be submitted with the conclusion of the clinical study. CSPH is considered the accepted indication for liver cirrhosis severity assessment. The market potential for the developed diagnostic test is estimated by Exalenz at $100 million a year.